SunGen Pharma, a privately held specialty pharmaceutical company, has launched and started commercial shipment of a generic version of Bentyl (Dicyclomine) Injection in the United States, it was reported on Friday.
The product has been launched in collaboration with Camber Pharmaceuticals as SunGen's distribution and marketing partner.
Dicyclomine Hydrochloride Injection USP, 20mg/2mL (10mg/mL) is a sterile injectable in a two ml-vial. It is used to treat patients with severe irritable bowel syndrome and bowel spasms. It had total US sales of USD17m for 2018 according to IQVIA.
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment